HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE
Post-LOEhydrocodone bitartrate and homatropine methylbromide
ANDAORALSYRUP
Approved
Feb 2017
Lifecycle
Post-LOE
Competitive Pressure
30/100
Data completeness
2/8 — Basic
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE (hydrocodone bitartrate and homatropine methylbromide) by Teva is mu-opioid receptor, although it can interact with other opioid receptors at higher doses. First approved in 2017.
Drug data last refreshed 18h ago
Mechanism of Action
mu-opioid receptor, although it can interact with other opioid receptors at higher doses. The precise mechanism of action of hydrocodone and other opiates is not known; however, hydrocodone is believed to act centrally on the cough center. In excessive doses, hydrocodone will depress respiration.…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Company
Teva
Worked on HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.